Página 1 desde 19 resultados
FIELD OF THE INVENTION
The present invention relates to 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, which is a compound of formula
##STR00002## and to pharmaceutically acceptable acid addition salts thereof. This compound is generically
TECHNICAL FIELD
Embodiments disclosed herein generally relate to a method of treatment for weight-loss and other conditions in a mammal. More particularly, embodiments herein are directed to anatomically targeted, low-dosage delivery of antiepileptic/anticonvulsant compounds for weight-loss and
BACKGROUND OF THE INVENTION
The present invention generally relates to pyridone substituted benzothiazole compounds that are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A.sub.2A -receptor and a high selectivity to the A.sub.1 - and
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
BACKGROUND OF THE INVENTION
Serotonin (5-hydroxy-tryptamine) (5-HT) receptors play an important role in many physiological and pathological functions like anxiety, sleep regulation, aggression, feeding and depression. The 5-HT receptors are distributed throughout the body and can be divided is into
TECHNICAL FIELD
The present invention is in the field of chemical synthesis of stereoisomers and more particularly the exo-S-mecamylamine stereoisomer and the use of exo-S-mecamylamine in medical treatments.
BACKGROUND ART
Mecamylamine (N,2,3,3-tetramethylbicyclo-[2.1.1]heptan-2-amine hydrochloride,
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. TOPIRAMATE
Topiramate is a
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. Topiramate
Topiramate is a
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. Topiramate
Topiramate is a
BACKGROUND OF THE INVENTION
In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor.
L-glutamic acid, the most commonly occurring neurotransmitter in the CNS, plays a critical role in a
BACKGROUND
(1) Field of the Invention
The present invention is in the field of chemical synthesis of stereoisomers and more particularly the exo-S-mecamylamine stereoisomer and the use of exo-S-mecamylamine in medical treatments.
(2) Description of Related Art
Mecamylamine